-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The net result for the period of deducting operating expenses from operating revenues.
-
Summary
-
Sigilon Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q1 2020 to Q2 2023.
- Sigilon Therapeutics, Inc. Operating Income (Loss) for the quarter ending June 30, 2023 was -$7.44M, a 47% increase year-over-year.
- Sigilon Therapeutics, Inc. Operating Income (Loss) for the twelve months ending June 30, 2023 was -$30.8M, a 52.2% increase year-over-year.
- Sigilon Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$43.7M, a 42.3% increase from 2021.
- Sigilon Therapeutics, Inc. annual Operating Income (Loss) for 2021 was -$75.6M, a 43.7% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)